Ototoxic effect of cytostatic platinum-based drug

Ototoxicity refers to the hearing impairment that results from the temporary or permanent inner ear dysfunction after treatment with an ototoxic drug. Other drug classes known to have ototoxic properties include aminoglycosides, loop diuretics, quinine, nonsteroidal anti-inflammatory drugs, and antiretroviral therapy. Platinum-based chemotherapy drugs are effective drugs used to treat many types of malignant neoplasms. However, its ototoxic potential puts cancer patients at risk of hearing loss. This, in turn, negatively affects the patient’s quality of life. It is essential for clinicians working with these patients to be aware of the ototoxic properties of platinum preparations and the clinical signs in order to identify patients at risk of developing hearing loss. The review identified peer-reviewed articles available from January 1975 to July 2019 on the monitoring of cytotopic toxicity and ototoxicity associated with cisplatin, and included only articles in English. The same researcher conducted a literature search and reviewed abstracts and articles for inclusion in the study. The studies were identified using a MeSH (Medical Subject Headings) keyword and term search in electronic databases. A manual search for relevant authors and journals was also completed. The links cited by each publication, review, or book chapter were reviewed to find additional potential publications. This article provides an updated review of the ototoxicity associated with platinum-based chemotherapy drugs.

Download Full-text

A Review of Cisplatin-Associated Ototoxicity

Seminars in Hearing ◽

10.1055/s-0039-1684041 ◽

2019 ◽

Vol 40 (02) ◽

pp. 108-121 ◽

Cited By ~ 7

Author(s):

Jessica Paken ◽

Cyril Govender ◽

Mershen Pillay ◽

Vikash Sewram

Keyword(s):

Quality Of Life ◽

Risk Factors ◽

At Risk ◽

Health Care Professionals ◽

Monitoring Program ◽

Clinical Signs ◽

Incidence Rates ◽

Cellular Mechanisms ◽

Patients At Risk

AbstractCisplatin, an effective antineoplastic drug used in the treatment of many cancers, has ototoxic potential, thus placing cancer patients, receiving this treatment, at risk of hearing loss. It is therefore important for health care professionals managing these patients to be aware of cisplatin's ototoxic properties and its clinical signs to identify patients at risk of developing a hearing impairment. Eighty-five English peer-reviewed articles and two books, from January 1975 to July 2015, were identified from PubMed, ScienceDirect, and EBSCOhost. An overview of cisplatin-associated ototoxicity, namely its clinical features, incidence rates, molecular and cellular mechanisms, and risk factors, is presented in this article. This review further highlights the importance of a team-based approach to complement an audiological monitoring program in reducing any further loss in the quality of life of affected patients, as there is currently no otoprotective agent routinely recommended for the prevention of cisplatin-associated ototoxicity.

Download Full-text

Hearing loss as a complication of stapes surgery

Otolaryngology ◽

10.1016/s0194-5998(96)70046-3 ◽

1996 ◽

Vol 115 (4) ◽

pp. 324-328 ◽

Cited By ~ 32

Author(s):

Wolf J. Mann ◽

Ronald G. Amedee ◽

Gudrun Fuerst ◽

Harold G. Tabb

Keyword(s):

At Risk ◽

Hearing Loss ◽

Sensorineural Hearing Loss ◽

Postoperative Period ◽

Stapes Surgery ◽

Morbidity Rate ◽

Profound Hearing Loss ◽

Patients At Risk ◽

Revision Operations ◽

Head Neck

During a 10-year period (1984–1994) 1229 stapes operations for otosclerosis were performed at our respective institutions by experienced surgeons well trained in the various techniques. Procedures included 691 stapedectomies, 234 small-fenestrae stapedotomies, and 304 revision operations. These primary and revision cases resulted in 20 ears with severe sensorineural hearing loss or anacusis noted during the immediate postoperative period. This article will critically evaluate those procedures that resulted in profound hearing loss and attempt to determine possible reasons for this occurrence. It is hoped that these data will allow surgeons to identify before and/or during surgery patients at risk for development of this complication and therefore decrease the overall morbidity rate of this exacting procedure. (Otolaryngol Head Neck Surg 1996;115:324–8.)

Download Full-text

Cisplatin-Associated Ototoxicity: A Review for the Health Professional

Journal of Toxicology ◽

10.1155/2016/1809394 ◽

2016 ◽

Vol 2016 ◽

pp. 1-13 ◽

Cited By ~ 43

Author(s):

Jessica Paken ◽

Cyril D. Govender ◽

Mershen Pillay ◽

Vikash Sewram

Keyword(s):

Quality Of Life ◽

Health Care ◽

At Risk ◽

Hearing Loss ◽

Clinical Signs ◽

Policy Formulation ◽

Incidence Rates ◽

Health Care Practitioners ◽

Mesh Terms

Cisplatin is an effective drug used in the treatment of many cancers, yet its ototoxic potential places cancer patients, exposed to this drug, at risk of hearing loss, thus negatively impacting further on a patient’s quality of life. It is paramount for health care practitioners managing such patients to be aware of cisplatin’s ototoxic properties and the clinical signs to identify patients at risk of developing hearing loss. English peer-reviewed articles from January 1975 to July 2015 were assessed from PubMed, Science Direct, and Ebscohost. Seventy-nine articles and two books were identified for this review, using MeSH terms and keywords such as “ototoxicity”, “cisplatin”, “hearing loss”, and “ototoxicity monitoring”. This review provides an up-to-date overview of cisplatin-associated ototoxicity, namely, its clinical features, incidence rates, and molecular and cellular mechanisms and risk factors, to health care practitioners managing the patient with cancer, and highlights the need for a team-based approach to complement an audiological monitoring programme to mitigate any further loss in the quality of life of affected patients, as there is currently no otoprotective agent recommended routinely for the prevention of cisplatin-associated ototoxicity. It also sets the platform for effective dialogue towards policy formulation and strengthening of health systems in developing countries.

Download Full-text

Prevalence and risk factors of hearing loss in children with solid tumors treated with platinum-based chemotherapy

Paediatrica Indonesiana ◽

10.14238/pi55.3.2015.121-5 ◽

2015 ◽

Vol 55 (3) ◽

pp. 121

Author(s):

Eka D Edward ◽

Nelly Rosdiana ◽

Farhat Farhat ◽

Olga Rasiyanti Siregar ◽

Bidasari Lubis

Keyword(s):

Risk Factors ◽

Hearing Loss ◽

Solid Tumors ◽

Otoacoustic Emission ◽

Cross Sectional Study ◽

Eligibility Criteria ◽

Cross Sectional ◽

Chemotherapy Drugs ◽

Platinum Based Chemotherapy ◽

Significant Difference

Background The platinum-based chemotherapy drugs, cisplatin and carboplatin, are widely used in the treatment of several types of solid tumors. However, the treatment has side effects including hearing loss.Objective To evaluate the prevalence of hearing loss related to platinum-based chemotherapy and to identify associated factors.Methods A cross-sectional study was performed in Adam Malik Hospital, Medan, North Sumatera, from April to July 2012. Twenty-two subjects who fulfilled the eligibility criteria underwent otoacoustic emission evaluations. Eleven children had received cisplatin and eleven had received carboplatin. The association between hearing loss and risk factors was assessed using Fisher’s exact and Chi-square tests.Results Seven subjects with hearing loss were identified. Five of these patients (5 out of 11) had received cisplatin and 2 patients (2 out of 11) had received carboplatin. There was no statistically significant difference between carboplatin- and cisplatin-associated hearing loss (P=0.361). Neither gender (P=0.452) nor age (P=0.212) was related to hearing loss. However, higher cumulative chemotherapy doses (cisplatin >600 mg/m² and carboplatin >1800 mg/m²) were associated with hearing loss (P=0.022 and P=0.004, respectively).Conclusion Patients who had higher cumulative doses of platinum-based chemotherapy are at risk for developing hearing loss.

Download Full-text